Medicine and Dentistry
Inflammatory Bowel Disease
100%
Crohn's Disease
57%
Infliximab
51%
Ulcerative Colitis
36%
Ustekinumab
34%
Prospective Cohort Study
27%
Tumor Necrosis Factor
25%
Diseases
25%
Patient with Crohn's Disease
23%
Vedolizumab
20%
Adalimumab
19%
Colonoscopy
18%
Biosimilar
17%
Biological Product
17%
Prevalence
13%
Disease Activity
10%
Spontaneous Remission
9%
Cohort Analysis
8%
Recurrent Disease
8%
Acute Graft Versus Host Disease
8%
End to End Anastomosis
8%
Liver Injury
8%
TNF Inhibitor
8%
Liver Graft
8%
Transient Elastography
8%
Anal Fistula
8%
Dysplasia
8%
Postoperative Complication
8%
Etanercept
8%
Tacrolimus
8%
Randomized Controlled Trial
8%
Cardiovascular System
8%
Meta-Analysis
8%
Oral
8%
Secondary Loss
8%
Vegetarian Diet
8%
Clinical Assessment
8%
Trough Level
8%
Multivariate Analysis
7%
Odds Ratio
7%
Patient with Inflammatory Bowel Disease
7%
Cytokine
7%
Body Mass Index
7%
Immunomodulating Agent
7%
Magnetic Resonance Imaging
6%
C Reactive Protein
6%
Faecal Calprotectin
6%
Hazard Ratio
6%
Monoclonal Antibody
6%
Colectomy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
79%
Crohn's Disease
48%
Remission
46%
Ustekinumab
34%
Infliximab
28%
Prospective Cohort Study
27%
Vedolizumab
20%
Ulcerative Colitis
14%
Tumor Necrosis Factor
14%
Cohort Study
13%
Biological Product
13%
Adalimumab
10%
Randomized Controlled Trial
9%
Dysplasia
8%
Biosimilar Agent
8%
Etanercept
8%
Tacrolimus
8%
Acute Graft Versus Host Disease
8%
Tumor Necrosis Factor Inhibitor
8%
Inflammatory Disease
8%
Diseases
8%
Trough Level
8%
Immunomodulating Agent
7%
Glucagon Like Peptide 1 Receptor Agonist
6%
Necrosis
5%
Cytokine
5%
Cardiovascular Disease
5%
Immunology and Microbiology
Inflammatory Bowel Disease
53%
Crohn's Disease
51%
Infliximab
43%
Ustekinumab
34%
Biosimilar Agent
17%
Ulcerative Colitis
15%
Adalimumab
10%
Acute Graft Versus Host Disease
8%
Etanercept
8%
TNF Inhibitor
8%
Prevalence
8%
Tumor Necrosis Factor Alpha
8%
Body Mass
8%
Immunomodulating Drugs
7%
C-Reactive Protein
6%
Cytokine
6%
Liver Transplantation
5%